Please assess the completion status of the following clinical trial:

Trial Title: Trial of Lithium Carbonate for Treatment of Osteoporosis-pseudoglioma Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Eligibility Criteria~Inclusion Criteria~* Age 4 years or greater~* Diagnosed with osteoporosis pseudoglioma syndrome (OPPG) or a first degree relative of someone with OPPG. For diagnosis of OPPG, one of the following is required: (1) congenital blindness in a child born into a family with known OPPG where at least one affected family member has had an LRP5 mutation demonstrated or (2) a child with no known family members with OPPG who has congenital blindness, DXA Z-score \< -2.0 and mutation in LRP5 documented~* No contraindications to lithium carbonate~* For women of child bearing age, willing to undergo urine pregnancy test~Exclusion Criteria~* Age under 4 years~* Not diagnosed with osteoporosis pseudoglioma (OPPG) syndrome or a first degree relative of someone with OPPG, or a member of the Old Order Mennonite community~* Pregnant~* For women of childbearing age, not willing to undergo urine pregnancy test~* Contraindication to Lithium (serum creatinine \> 1.3, known cardiovascular disease \[history of myocardial infarction, heart failure\], currently on diuretic or ACE inhibitor)~* Glomerular filtration rate below 80 cc/min

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Lithium (Type: EXPERIMENTAL): patients with OPPG will be treated with lithium for 6 months
- Unaffected controls (Type: NO_INTERVENTION): Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.

Based on this trial design, predict the completion outcome and termination type (if applicable).